在糖尿病老鼠身上对Medicago sativa L. (Fabaceae) 的胃保护性评估
Phool Chandra1, Mohammad Kaleem2, Neetu Sachan3
1Teerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Moradabad, U.P. 244001, India.
概括
乙醇提取物Medicago sativa () 在糖尿病大鼠中表现出显著的抗活性,降低了指数和酸度. 这种提取物还对肝脏和脏提供保护作用,并具有抗高血糖作用.
科学领域:
- 药理学 药理学是指药理学的学科.
- 胃肠病学 胃肠病学
- 糖尿病学 糖尿病学
背景情况:
- 梅西卡戈 (Medicago sativa) () 传统上用于保护肝脏和消化系统问题.
- 糖尿病可以加剧胃肠道问题,包括胃.
- 有限的研究存在于在治疗糖尿病模型的有效性.
研究的目的:
- 评估Medicago sativa (EEMS) 乙醇提取物在糖尿病大鼠实验诱导的胃中的抗潜力.
- 评估EEMS在糖尿病背景下对胃酸,指数和器官保护的影响.
- 调查EEMS的潜在抗高血糖作用.
主要方法:
- 在老鼠中,使用螺柱体结合和乙醇给药诱导了胃.
- 通过使用aloxan诱导糖尿病.
- 鼠被分为接受载体,拉尼蒂丁 (阳性对照) 或EEMS的100和400毫克/公斤的组.
- 评估了指数,自由酸度和器官组织学. 还评估了抗高血糖活性.
主要成果:
- 根据剂量,EEMS显著降低了指数 (p < 0.001).
- 在两次测试剂量中,EEMS降低了胃自由酸度.
- 提取物对肝脏和脏表现出保护作用,并对糖尿病大鼠表现出抗高血糖活性.
结论:
- 麦迪卡戈 (Medicago sativa) 的乙醇提取物在糖尿病老鼠中具有显著的抗性质.
- 在糖尿病患者中,EEMS可以作为治疗胃的治疗选择.
- 需要进一步的研究来阐明其确切的作用机制.
相关概念视频
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
184
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
184
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
212
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
212